These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 33987383)

  • 1. Perioperative safety and feasibility outcomes of stage IIIA-N2 non-small cell lung cancer following neoadjuvant immunotherapy or neoadjuvant chemotherapy: a retrospective study.
    Huang Z; Wu Z; Qin Y; Zhao Y; Xuan Y; Qiu T; Liu A; Dong Y; Su W; Du W; Yun T; Wang L; Liu D; Sun L; Jiao W
    Ann Transl Med; 2021 Apr; 9(8):685. PubMed ID: 33987383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.
    Pless M; Stupp R; Ris HB; Stahel RA; Weder W; Thierstein S; Gerard MA; Xyrafas A; Früh M; Cathomas R; Zippelius A; Roth A; Bijelovic M; Ochsenbein A; Meier UR; Mamot C; Rauch D; Gautschi O; Betticher DC; Mirimanoff RO; Peters S;
    Lancet; 2015 Sep; 386(9998):1049-56. PubMed ID: 26275735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and effectiveness of neoadjuvant immunotherapy combined with chemotherapy followed by surgical resection in patients with stage I-IIIA small-cell lung cancer: a retrospective single-arm clinical trial.
    Liu J; Wang L; Shu W; Zhang L; Wang Y; Lv W; Zhu L; Hu J
    J Thorac Dis; 2022 Nov; 14(11):4405-4415. PubMed ID: 36524062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary experience of surgery after neoadjuvant immunotherapy combined with chemotherapy for stage-IIIB non-small cell lung cancer.
    Ding Y; Zhao X; Christopoulos P; Geraci TC; Fu Y
    J Thorac Dis; 2024 Jul; 16(7):4645-4654. PubMed ID: 39144346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world clinical outcomes of neoadjuvant immunotherapy combined with chemotherapy in resectable non-small cell lung cancer.
    Wu J; Hou L; E H; Zhao Y; Yu X; Xu L; Ning Y; Deng J; Sun K; Zhang J; Wu C; Zhu Y; Zhao D; She Y; Su C; Chen C
    Lung Cancer; 2022 Mar; 165():115-123. PubMed ID: 35123154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open, observational clinical study of neoadjuvant therapy in resectable stage III non-small cell lung cancer.
    Qi Y; Gu L; Shen J; Yao Y; Zhao Y; Lu S; Chen Z
    Front Oncol; 2023; 13():1194100. PubMed ID: 37655106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
    Rothschild SI; Zippelius A; Eboulet EI; Savic Prince S; Betticher D; Bettini A; Früh M; Joerger M; Lardinois D; Gelpke H; Mauti LA; Britschgi C; Weder W; Peters S; Mark M; Cathomas R; Ochsenbein AF; Janthur WD; Waibel C; Mach N; Froesch P; Buess M; Bohanes P; Godar G; Rusterholz C; Gonzalez M; Pless M;
    J Clin Oncol; 2021 Sep; 39(26):2872-2880. PubMed ID: 34251873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of neoadjuvant chemo-immunotherapy in non-small cell lung cancer: a real-world, multicenter, retrospective study.
    Wang X; Wang X; Hui B; Cai J; Zhao H; Qiao B; Duan J; Chen K; Wang J; Lei J; Yang F
    Transl Lung Cancer Res; 2024 Apr; 13(4):849-860. PubMed ID: 38736498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety evaluation of neoadjuvant immunotherapy plus chemotherapy for resectable non-small cell lung cancer in real world.
    Fang M; Hang Q; Jiang H; Cai L; Hu J; Ying H; Gu Q; Yu X; Liu J; Lai X
    Front Oncol; 2022; 12():1055610. PubMed ID: 36713546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B (Discrete N2) Non-small-cell Lung Cancer: SQUAT trial (WJOG 12119L).
    Hamada A; Soh J; Hata A; Nakamatsu K; Shimokawa M; Yatabe Y; Oizumi H; Tsuboi M; Horinouchi H; Yoshino I; Tanahashi M; Toyooka S; Okada M; Yokomise H; Yamashita M; Nishimura Y; Yamamoto N; Nakagawa K; Mitsudomi T
    Clin Lung Cancer; 2021 Nov; 22(6):596-600. PubMed ID: 34034990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of mediastinal lymph node status and relapse pattern in clinical stage IIIA non-small cell lung cancer patients treated with neoadjuvant chemotherapy versus upfront surgery: A single center experience.
    Savic M; Kontic M; Ercegovac M; Stojsic J; Bascarevic S; Moskovljevic D; Kostic M; Vesovic R; Popevic S; Laban M; Markovic J; Jovanovic D
    Thorac Cancer; 2017 Sep; 8(5):393-401. PubMed ID: 28671758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Application of Neoadjuvant Chemoimmunotherapy in Resectable NSCLC].
    Wang H; Han Y
    Zhongguo Fei Ai Za Zhi; 2023 Nov; 26(11):822-832. PubMed ID: 38061884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis.
    Xu YP; Li B; Xu XL; Mao WM
    Medicine (Baltimore); 2015 Jun; 94(23):e879. PubMed ID: 26061306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
    Provencio M; Nadal E; Insa A; García-Campelo MR; Casal-Rubio J; Dómine M; Majem M; Rodríguez-Abreu D; Martínez-Martí A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé Caro R; Viñolas N; Barneto Aranda I; Viteri S; Pereira E; Royuela A; Casarrubios M; Salas Antón C; Parra ER; Wistuba I; Calvo V; Laza-Briviesca R; Romero A; Massuti B; Cruz-Bermúdez A
    Lancet Oncol; 2020 Nov; 21(11):1413-1422. PubMed ID: 32979984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of Pulmonary Resection and Mediastinal Node Dissection by Video-Assisted Thoracoscopic Surgery Following Neoadjuvant Chemoradiation Therapy for Stage IIIA N2 Non-Small Cell Lung Cancer.
    Jeon YJ; Choi YS; Lee KJ; Lee SH; Pyo H; Choi JY
    Korean J Thorac Cardiovasc Surg; 2018 Feb; 51(1):29-34. PubMed ID: 29430426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety and efficacy of neoadjuvant programmed death 1 inhibitor therapy with surgical resection in stage IIIA non-small cell lung cancer.
    Wang J; Li J; Cai L; Chen S; Jiang Y
    Ann Transl Med; 2021 Mar; 9(6):486. PubMed ID: 33850883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant Immuno-Chemotherapy: A New Perspective for Stage III NSCLC?
    Yao Y; Tang D; Gao W; Zhang H
    Front Surg; 2022; 9():843987. PubMed ID: 35449550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant pembrolizumab and chemotherapy in resectable clinical stage III non-small-cell lung cancer: a retrospective cohort study.
    Zhao G; Zhang H; Xu F; Lu C; Zhu Q; Grossi F; Divisi D; Ma T; Gu J; Ge D
    Transl Lung Cancer Res; 2023 Jan; 12(1):141-149. PubMed ID: 36762056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining antiangiogenic therapy with neoadjuvant chemotherapy increases treatment efficacy in stage IIIA (N2) non-small cell lung cancer without increasing adverse effects.
    Zhao X; Su Y; You J; Gong L; Zhang Z; Wang M; Zhao Z; Zhang Z; Li X; Wang C
    Oncotarget; 2016 Sep; 7(38):62619-62626. PubMed ID: 27566586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgical perspective in neoadjuvant chemoimmunotherapy for stage II-III non-small cell lung cancer.
    Hong T; Sun T; Zhang M; Liu X; Yuan Y; Dolo PR; Chen B; Zhang H
    Thorac Cancer; 2021 Oct; 12(20):2796-2802. PubMed ID: 34463034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.